CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine UCSD UCSF
- Dates
- study startestimated completion
- Principal Investigator
- by Lyudmila Bazhenova (ucsd)Misako Nagasaka (uci)Katy Tsai, MD (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientists at University of California Health
- Lyudmila Bazhenova (ucsd)
Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators. - Misako Nagasaka (uci)
Associate Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 139 research publications - Katy Tsai, MD (ucsf)
Dr. Katy K. Tsai is a medical oncologist and clinical researcher who specializes in treating advanced melanoma and other non-melanoma skin cancers, such as squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma. Dr. Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- BioAtla, Inc.
- ID
- NCT03504488
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 420 study participants
- Last Updated